Associations between private vaccine and antimicrobial consumption across Indian states, 2009–2017

Schueller, Emily; Nandi, Arindam; Joshi, Jyoti; Laxminarayan, Ramanan; Klein, Eili Y.

doi:10.1111/nyas.14571

Cited by 8 publications

(3 citation statements)

References 54 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent analysis of a trial for an experimental respiratory syncytial virus vaccine showed promising results in reducing antibiotic usage [98,99]. Maternal vaccination could prevent around 3.6 antimicrobial prescription courses per 100 infants in HICs and 5.1 courses per 100 infants in LMICs [100][101][102]. This underlines the connection between vaccination and reduced antibiotic usage.…”

Section: Vaccination Drivesmentioning

confidence: 99%

Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward

Kanan,

Ramadan,

Haif

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Antibiotic overuse poses a critical global health concern, especially in low- and middle-income countries (LMICs) where access to quality healthcare and effective regulatory frameworks often fall short. This issue necessitates a thorough examination of the factors contributing to antibiotic overuse in LMICs, including weak healthcare infrastructure, limited access to quality services, and deficiencies in diagnostic capabilities. To address these challenges, regulatory frameworks should be implemented to restrict non-prescription sales, and accessible point-of-care diagnostic tools must be emphasized. Furthermore, the establishment of effective stewardship programs, the expanded use of vaccines, and the promotion of health systems, hygiene, and sanitation are all crucial components in combating antibiotic overuse. A comprehensive approach that involves collaboration among healthcare professionals, policymakers, researchers, and educators is essential for success. Improving healthcare infrastructure, enhancing access to quality services, and strengthening diagnostic capabilities are paramount. Equally important are education and awareness initiatives to promote responsible antibiotic use, the implementation of regulatory measures, the wider utilization of vaccines, and international cooperation to tackle the challenges of antibiotic overuse in LMICs.

show abstract

Section: Vaccination Drivesmentioning

confidence: 99%

Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward

Kanan,

Ramadan,

Haif

et al. 2023

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Panel regression techniques have been used, for example, to assess the relationship between vaccination and AMU in Indian states [ 39 ], the relationship between medical staffing and resistance prevalence in Chinese provinces [ 40 , 41 ], the relationship between lab capacity and AMR in European countries [ 42 ]; and the association between animal AMR and AMU, and animal AMR and human AMR, in European countries [ 43 ].…”

Section: Alternative Ways Of Assessing This Relationshipmentioning

confidence: 99%

Quantifying the Relationship between Antibiotic Use in Food-Producing Animals and Antibiotic Resistance in Humans

et al. 2022

View full text Add to dashboard Cite

It is commonly asserted that agricultural production systems must use fewer antibiotics in food-producing animals in order to mitigate the global spread of antimicrobial resistance (AMR). In order to assess the cost-effectiveness of such interventions, especially given the potential trade-off with rural livelihoods, we must quantify more precisely the relationship between food-producing animal antimicrobial use and AMR in humans. Here, we outline and compare methods that can be used to estimate this relationship, calling on key literature in this area. Mechanistic mathematical models have the advantage of being rooted in epidemiological theory, but may struggle to capture relevant non-epidemiological covariates which have an uncertain relationship with human AMR. We advocate greater use of panel regression models which can incorporate these factors in a flexible way, capturing both shape and scale variation. We provide recommendations for future panel regression studies to follow in order to inform cost-effectiveness analyses of AMR containment interventions across the One Health spectrum, which will be key in the age of increasing AMR.

show abstract

“…Vaccines are a powerful tool against the emergence and spread of antimicrobial resistance (AMR). By reducing both drug-resistant and sensitive infections 14 , 20 – 22 , vaccines reduce reliance on drug therapies and selective pressure driving resistance, averting significant health and economic burden 14 . The World Health Organization has recognized the role of vaccines in combatting AMR and has developed a strategy to optimize the use of vaccines for this purpose 14 , 20 , 21 , 23 – 26 .…”

Section: Introductionmentioning

confidence: 99%

Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries

Hamilton,

Haghpanah,

Hasso-Agopsowicz

et al. 2023

Commun Med

Self Cite

View full text Add to dashboard Cite

Background The emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control. This study aims to inform policymakers and vaccine developers on the potential of an effective malaria vaccine in reducing drug-resistant infections. Methods A compartmental model estimating cases, drug-resistant cases, and deaths averted from 2021 to 2030 with a vaccine against Plasmodium falciparum infection administered yearly to 1-year-olds in 42 African countries. Three vaccine efficacy (VE) scenarios and one scenario of rapidly increasing drug resistance are modeled. Results When VE is constant at 40% for 4 years and then drops to 0%, 235.7 (Uncertainty Interval [UI] 187.8–305.9) cases per 1000 children, 0.6 (UI 0.4–1.0) resistant cases per 1000, and 0.6 (UI 0.5–0.9) deaths per 1000 are averted. When VE begins at 80% and drops 20 percentage points each year, 313.9 (UI 249.8–406.6) cases per 1000, 0.9 (UI 0.6–1.3) resistant cases per 1000, and 0.9 (UI 0.6–1.2) deaths per 1000 are averted. When VE remains 40% for 10 years, 384.7 (UI 311.7–496.5) cases per 1000, 1.0 (0.7–1.6) resistant cases per 1000, and 1.1 (UI 0.8–1.5) deaths per 1000 are averted. Assuming an effective vaccine and an increase in current levels of drug resistance to 80% by 2030, 10.4 (UI 7.3–15.8) resistant cases per 1000 children are averted. Conclusions Widespread deployment of a malaria vaccine could substantially reduce health burden in Africa. Maintaining VE longer may be more impactful than a higher initial VE that falls rapidly.

show abstract

Associations between private vaccine and antimicrobial consumption across Indian states, 2009–2017

Cited by 8 publications

References 54 publications

Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward

Empowering Low- and Middle-Income Countries to Combat AMR by Minimal Use of Antibiotics: A Way Forward

Quantifying the Relationship between Antibiotic Use in Food-Producing Animals and Antibiotic Resistance in Humans

Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries

Contact Info

Product

Resources

About